ELEVIDYS Adds Older-Ambulatory Durability, With Comparator Risk Intact

Company Sarepta Therapeutics Event Type Clinical Data / Conference Presentation Modality AAV Gene Therapy Asset ELEVIDYS (delandistrogene moxeparvovec) Target DMD Gene / Micro-dystrophin Disease Area Duchenne Muscular Dystrophy Summary Sarepta reported new ELEVIDYS analyses at the World Muscle Society meeting. Twenty-five patients dosed at ages…